REDWOOD CITY, Calif.--(BUSINESS WIRE)--Integrated Biosciences, a biotechnology company pioneering the use of synthetic biology and machine learning to develop next-generation therapeutics for age-related diseases, today announced that it has closed a $17.2 million seed financing, led by Sutter Hill Ventures with participation from Root Ventures, Civilization Ventures, Illumina Ventures Labs, Lifespan Vision Ventures, Overlap Holdings, SH Fund (Sabrina Hahn), Conscience VC, Mission BioCapital, Reinforced Ventures, Polymath Capital, Michael Stoppelman, and Vijay Pandurangan.

加利福尼亚州红木市——（商业新闻短讯）——综合生物科学公司是一家生物技术公司，率先使用合成生物学和机器学习来开发与年龄有关的疾病的下一代治疗方法，今天宣布，它已经完成了一笔1720万美元的种子融资，由Sutter Hill Ventures牵头，来自Root Ventures、文明风投、Illumina Ventures Labs、Lifespan Vision Ventures、Overlap Holdings、SH Fund（Sabrina Hahn）、良心风投、Mission BioCapital、Reinforced Ventures、Polymath Capital、Michael Stoppelman和Vijay Panduragan的参与。

The company also announced that Keith Loebner, Ph.D. has been appointed to the company’s Board of Directors and that Karl Sylvester, M.D., Uri Alon, Ph.D., and Wendy B. Young, Ph.D. have been appointed as advisors to the company..

公司还宣布，Keith Loebner博士已被任命为公司董事会成员，Karl Sylvester博士、Uri Alon博士和Wendy B.Young博士已被任命为公司顾问。

“We started Integrated Biosciences to make real progress toward achieving healthier human aging,” said Felix Wong, Ph.D., Co-Founder and CEO. “The new capital will significantly advance our efforts toward this ambitious goal by enabling us to scale up our synthetic biology and AI platform while investing in the clinical development of our small-molecule portfolio.

联合创始人兼首席执行官Felix Wong博士说：“我们开始整合生物科学，以在实现更健康的人类衰老方面取得真正的进展。”。“新资本将大大推动我们朝着这一宏伟目标的努力，使我们能够扩大合成生物学和人工智能平台的规模，同时投资于我们小分子投资组合的临床开发。

Our world-class syndicate, led by Sutter Hill Ventures, represents visionary investors who appreciate our scientific progress and understand that we are an entirely different type of company, in terms of both our mission and our technology.”.

我们由Sutter Hill Ventures领导的世界级财团代表了富有远见的投资者，他们欣赏我们的科学进步，并理解我们在使命和技术方面是一家完全不同类型的公司。”

Founded in September 2022, Integrated Biosciences has consistently reported on its drug discovery engine in leading journals, including Nature, Nature Aging, and Cell Systems. Integrated Biosciences differentiates itself by using synthetic biology and optogenetics to control and generate highly specific data across different cellular phenotypes.

Integrated Biosciences成立于2022年9月，一直在领先期刊上报道其药物发现引擎，包括Nature，Nature Aging和Cell Systems。综合生物科学通过使用合成生物学和光遗传学来控制和生成不同细胞表型的高度特异性数据，从而使自身与众不同。

This capability enables the company to identify new targets, modulate any biological pathway of interest, and deploy its proprietary AI platform to discover precise and novel small-molecule drug candidates. Having pioneered the first AI-driven discovery of a structural class of antibiotics last year, the company is now developing a portfolio of preclinical-stage assets to treat multiple age-related diseases..

。去年，该公司率先发现了人工智能驱动的结构类抗生素，目前正在开发临床前阶段资产组合，以治疗多种与年龄有关的疾病。

“Drug discovery is broken, and we are here to fix it,” said Max Wilson, Ph.D., Co-Founder. “Our synthetic biology platform gives us access to the purest stress responses, that alongside our chemistry and AI platforms allows us to rapidly produce small molecule leads that modulate these stress responses in novel ways.

联合创始人马克斯·威尔逊博士说：“药物发现被打破了，我们在这里修复它。”。“我们的合成生物学平台使我们能够获得最纯净的应激反应，与我们的化学和人工智能平台一起，使我们能够快速产生小分子导线，以新颖的方式调节这些应激反应。

What this means is that we can get more selective, structurally unique drug candidates faster by years, significantly increasing the efficiency of drug candidate development. Our track record already proves this. Looking ahead, we envision a future where targeting aging is tractable and age-related diseases are eradicated.”.

这意味着我们可以更快地获得更多选择性，结构独特的候选药物，从而显着提高候选药物开发的效率。我们的业绩记录已经证明了这一点。展望未来，我们设想未来，针对衰老的目标是容易处理的，与年龄有关的疾病被根除。”

Integrated Biosciences has assembled an A-list of strategic advisors. The company’s Scientific Advisory Board is chaired by James J. Collins, Ph.D., Termeer Professor of Medical Engineering and Science at MIT, and includes Sir David W. C. MacMillan Ph.D., winner of the 2021 Nobel Prize in Chemistry and James S.

综合生物科学公司（Integrated Biosciences）已经建立了一个战略顾问A级名单。该公司的科学顾问委员会由麻省理工学院医学工程与科学特米尔教授詹姆斯·柯林斯（JamesJ.Collins）博士担任主席，其中包括2021年诺贝尔化学奖获得者戴维·麦克米伦（DavidW.C.MacMillan）爵士（SirDavidW.C.MacMillan）博士和詹姆斯·s。

McDonnell Distinguished University Professor of Chemistry at Princeton. The announcement of Dr. Karl Sylvester, Dr. Uri Alon, and Dr. Wendy B. Young as advisors represents the company’s strengthening position in translational development. Dr. Sylvester is a Professor of Surgery and Pediatrics, Associate Dean of Maternal and Child Health Research at Stanford, and Co-Director of the Stanford Metabolic Health Center.

麦克唐纳是普林斯顿大学杰出的化学教授。宣布卡尔·西尔维斯特博士、乌里·阿隆博士和温迪·B·杨博士担任顾问代表了公司在转化发展中的强化地位。西尔维斯特博士是外科和儿科教授，斯坦福大学妇幼健康研究副院长，斯坦福代谢健康中心联合主任。

Dr. Alon, a Professor at the Weizmann Institute of Science in Israel and the Head of the Sagol Center for Longevity Research, studies aging from a systems biology and systems medicine perspective. Dr. Young is an advisor to Google Ventures and has more than 30 years of experience in the discovery and development of new medicines and research platforms, having served as Senior Vice President of Genentech’s Small Molecule Drug Discovery division..

以色列魏茨曼科学研究所教授、萨戈尔长寿研究中心主任阿隆博士从系统生物学和系统医学的角度研究衰老。杨博士是谷歌风险投资公司的顾问，在新药和研究平台的发现和开发方面拥有30多年的经验，曾担任基因泰克小分子药物发现部门的高级副总裁。

“Integrated Biosciences is unique in that the company has demonstrated time and again that it can consistently produce meaningful scientific results bridging basic research with real drug development,” said Dr. Collins, who last year was named a Clarivate Citation Laureate for scientific work deemed to be of Nobel class.

柯林斯博士说：“综合生物科学的独特之处在于，该公司一再证明，它可以始终如一地产生有意义的科学成果，将基础研究与真正的药物开发联系起来。”柯林斯博士去年因被认为是诺贝尔级的科学工作而被任命为克拉维特引文奖获得者。

“From inventing new synthetic biology-based platforms that upend traditional drug screening to developing drug candidates for clinical testing, Integrated is well-poised to continue generating substantial value.”.

“从发明颠覆传统药物筛选的基于合成生物学的新平台到开发用于临床测试的候选药物，Integrated有望继续产生巨大价值。”

Integrated Biosciences plans to use the new funding to accelerate the development of its drug pipeline, further develop its platform, and advance its commercialization efforts. The company’s approach of targeting fundamental, age-related pathways on the phenotypic level enables it to develop assets that have broad applicability to treating diverse diseases.

综合生物科学计划利用新资金加速其药物管道的开发，进一步开发其平台，并推进其商业化努力。该公司在表型水平上针对与年龄相关的基本途径的方法使其能够开发出广泛适用于治疗多种疾病的资产。

Building on its strength in rapidly discovering and developing assets, the company is pursuing a multi-asset business model in which assets will be advanced through a combination of company-led development and co-development partnerships..

凭借其快速发现和开发资产的实力，该公司正在寻求一种多资产商业模式，通过公司主导的开发和共同开发伙伴关系的结合来推进资产。

“We’re taking a less-trodden approach to drug discovery and development, with the goal of developing multiple drug candidates where each can bring substantial value,” said Satotaka Omori, Ph.D., Head of Aging Biology and a member of the company’s founding team. “This type of diversified approach fully leverages our ability to phenotypically target different age-related pathways.

“我们正在采取一种不太受欢迎的药物发现和开发方法，目标是开发多种候选药物，每种候选药物都能带来巨大价值，”衰老生物学负责人、该公司创始团队成员Satotaka Omori博士说。“这种多样化的方法充分利用了我们在表型上针对不同年龄相关途径的能力。

The industry should take note, because we move fast.”.

业界应该注意，因为我们行动迅速。”

Integrated Biosciences maintains several partnerships with private companies and a previously announced partnership with Illumina Ventures Labs. Integrated Biosciences’ partnerships will enable it to pursue large-scale projects and differentiated commercialization routes. The company’s drug discovery platform and unique commercialization routes contributed to attracting the attention of its advisors..

Integrated Biosciences与私营公司保持着几项合作关系，并与Illumina Ventures Labs保持着先前宣布的合作关系。综合生物科学的合作伙伴关系将使其能够进行大规模项目和差异化的商业化路线。该公司的药物发现平台和独特的商业化路线有助于吸引其顾问的注意力。

“I joined Integrated given the exciting and novel approach being pioneered to bridge the translation of fundamental biology to new clinical medicines,” said Dr. Sylvester. “As a practicing physician and translational scientist, I see tremendous opportunity in the approach Integrated is taking and value in the products that Integrated will develop to improve the lives of patients.

Sylvester博士说：“我加入了Integrated，因为它开创了一种令人兴奋和新颖的方法，将基础生物学的翻译与新的临床药物联系起来。”。“作为一名执业医生和转化科学家，我看到Integrated正在采取的方法带来了巨大的机会，Integrated将开发出的产品具有价值，以改善患者的生活。

The biology is exciting, the technology is exciting, and the company is exciting. I very much look forward to helping Integrated drive important clinical decisions and strategy.”.

生物学令人兴奋，技术令人兴奋，公司也令人兴奋。我非常期待帮助整合推动重要的临床决策和策略。”

Sutter Hill Ventures, a venture capital firm typically focused on originating companies, led the current fundraise, reflecting the unique synergy between the company’s scientific and clinical ambitions along with Sutter Hill Ventures’ company-building expertise. Sutter Hill Ventures pursues a limited number of external investments every year, and its past incubations and investments include Pure Storage, Snowflake, NVIDIA, GRAIL, and Helix..

萨特山风险投资公司（Sutter Hill Ventures）是一家通常专注于原始公司的风险投资公司，领导了当前的筹资活动，反映了该公司的科学和临床雄心与萨特山风险投资公司的公司建设专业知识之间的独特协同作用。萨特山风险投资公司每年进行的外部投资数量有限，其过去的孵化和投资包括Pure Storage、Snowflake、NVIDIA、GRAIL和Helix。

About Integrated Biosciences

关于Integrated Biosciences

Integrated Biosciences is a biotechnology company pioneering novel approaches that combine synthetic biology and AI-driven small-molecule drug discovery to produce next-generation therapeutics targeting age-related diseases. For more information, visit: www.integratedbiosciences.com.

Integrated Biosciences是一家生物技术公司，开创了将合成生物学和人工智能驱动的小分子药物发现相结合的新方法，以生产针对年龄相关疾病的下一代疗法。有关更多信息，请访问：www.integratedbiosciences.com。